News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Trastuzumab deruxtecan delivers long-term survival in HER2+ breast cancer
18 Jun 2024
byStephen Padilla
HER2-positive metastatic breast cancer (mBC) patients who had been treated with trastuzumab emtansine continue to enjoy survival benefits with trastuzumab deruxtecan (TD) relative to those who received treatment of physician’s choice (TPC), as shown by the updated results of the DESTINY-Breast (DB)-02 study. TD also boasts of a manageable safety profile, with no long-term toxicity.
18 Jun 2024

NMR helps tailor treatment for smoking cessation in smokers with COPD
18 Jun 2024
Among smokers with chronic obstructive pulmonary disease (COPD), use of varenicline seems better than bupropion in normal metabolizers, but bupropion displays similar efficacy and less side effects in slow metabolizers, reports a study.
18 Jun 2024







